230 related articles for article (PubMed ID: 27562750)
21. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
22. Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?
Bentur OS; Gurion R; Gafter-Gvili A; Gatt M; Shvidel L; Horowitz NA; Ram R; Herishanu Y; Sarid N; Paltiel O; Ganzel C; Kreiniz N; Dally N; Gutwein O; Raanani P; Avivi I; Perry C
Leuk Lymphoma; 2018 May; 59(5):1163-1171. PubMed ID: 28901817
[TBL] [Abstract][Full Text] [Related]
23. Outcome of patients with early-stage follicular lymphoma staged with
Ng SP; Khor R; Bressel M; MacManus M; Seymour JF; Hicks RJ; Wirth A
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):80-86. PubMed ID: 30083824
[TBL] [Abstract][Full Text] [Related]
24. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States.
Nastoupil LJ; Sinha R; Byrtek M; Zhou X; Taylor MD; Friedberg JW; Link BK; Cerhan JR; Dawson K; Flowers CR
Cancer; 2014 Jun; 120(12):1830-7. PubMed ID: 24668580
[TBL] [Abstract][Full Text] [Related]
25. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
Alonso-Álvarez S; Magnano L; Alcoceba M; Andrade-Campos M; Espinosa-Lara N; Rodríguez G; Mercadal S; Carro I; Sancho JM; Moreno M; Salar A; García-Pallarols F; Arranz R; Cannata J; Terol MJ; Teruel AI; Rodríguez A; Jiménez-Ubieto A; González de Villambrosia S; Bello JL; López L; Monsalvo S; Novelli S; de Cabo E; Infante MS; Pardal E; García-Álvarez M; Delgado J; González M; Martín A; López-Guillermo A; Caballero MD
Br J Haematol; 2017 Sep; 178(5):699-708. PubMed ID: 28782811
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma.
Le Dortz L; De Guibert S; Bayat S; Devillers A; Houot R; Rolland Y; Cuggia M; Le Jeune F; Bahri H; Barge ML; Lamy T; Garin E
Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2307-14. PubMed ID: 20717826
[TBL] [Abstract][Full Text] [Related]
27. Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma.
Zinzani PL; Musuraca G; Alinari L; Fanti S; Tani M; Stefoni V; Marchi E; Fina M; Pellegrini C; Castellucci P; Farsad M; Baccarani M
Clin Lymphoma Myeloma; 2007 Jan; 7(4):291-5. PubMed ID: 17324337
[TBL] [Abstract][Full Text] [Related]
28. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
[TBL] [Abstract][Full Text] [Related]
29. Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma.
Bishu S; Quigley JM; Bishu SR; Olsasky SM; Stem RA; Shostrom VK; Holdeman KP; Paknikar S; Armitage JO; Hankins JH
Leuk Lymphoma; 2007 Aug; 48(8):1548-55. PubMed ID: 17701586
[TBL] [Abstract][Full Text] [Related]
30. Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial.
Cottereau AS; Rebaud L; Trotman J; Feugier P; Nastoupil LJ; Bachy E; Flinn IW; Haioun C; Ysebaert L; Bartlett NL; Tilly H; Casasnovas O; Ricci R; Portugues C; Buvat I; Meignan M; Morschhauser F
Ann Oncol; 2024 Jan; 35(1):130-137. PubMed ID: 37898239
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of Treatment in Slovene Follicular Lymphoma Patients.
Južnič Šetina T; Borštnar S; Jezeršek Novaković B
Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):586-91. PubMed ID: 26423702
[TBL] [Abstract][Full Text] [Related]
32. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
[TBL] [Abstract][Full Text] [Related]
33. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
[TBL] [Abstract][Full Text] [Related]
34. PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study.
Tychyj-Pinel C; Ricard F; Fulham M; Fournier M; Meignan M; Lamy T; Vera P; Salles G; Trotman J
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):408-15. PubMed ID: 24435770
[TBL] [Abstract][Full Text] [Related]
35. Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information.
Nakajima R; Moskowitz AJ; Michaud L; Mauguen A; Batlevi CL; Dogan A; Schöder H
Blood Adv; 2020 Apr; 4(8):1812-1823. PubMed ID: 32343798
[TBL] [Abstract][Full Text] [Related]
36. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review.
Adams HJA; Nievelstein RAJ; Kwee TC
Ann Hematol; 2016 Jan; 95(1):11-18. PubMed ID: 26576560
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
39. Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy.
Maeng CH; Ahn SW; Ryu SY; Han S; Ko YH; Ji JH; Kim WS; Kim SJ
Korean J Intern Med; 2016 May; 31(3):560-9. PubMed ID: 26898595
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of first-line (131)I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic (18)F-fluorodeoxyglucose positron emission tomography.
McQuillan AD; Macdonald WB; Turner JH
Leuk Lymphoma; 2015 May; 56(5):1271-7. PubMed ID: 25065701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
